XV Congresso Nazionale Sihta

October 25-27, 2022 | Rome, Italy

We are pleased to share that we will be joining as speakers and sponsors XV Congresso Nazionale Sihta, a key event for Italian Healthcare industry.

Our speeches:
Digital Health e Real World Evidence: Valutazione di un modello a supporto di processi decisionali in ambito HTA

English title:
Digital Health and Real World Evidence: Evaluation of the Decision-Making Model in HTA

Firenze G. Monterosso A, Romeo J.

Presented by:
Giovanni Firenze, Market Access and Pricing Director, Italy, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Similitudini e differenze tra EUnetHTA e HTA nazionali: Aree di interesse per la futura metodologia HTA Europea

English title:
Similarities and Differences Between EUnetHTA and HTAs: Areas of Interest for the Future European HTA Methodology

Rabadi L, Couillerot AL, De la Paz I, Rodriguez N, Asmah A, Aguado M, Belamri M, Ottobrino V, Mangone M.

Presented by:
Monica Mangone, Global Market Access Senior Consultant, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Published on:
September 30, 2022
Our Speakers:
Giovanni Firenze

Giovanni Firenze

Market Access and Pricing Director, Italy, Alira Health Giovanni has started his career in Eli Lilly in Germany and in the UK as a Manager of a Sales & Marketing European Project, moving thereafter to Bristol Myers Squibb in the USA and later in Italy covering European positions.

In 2002, he joined the management consulting arena working for Arthur D. Little International, IMS Health Consulting Group (UK), as a Director, Executive Insight (Switzerland), HBI and Vintura.

During his career, Giovanni carried out and led multiple projects in different Therapeutic Areas, such as Respiratory, Cardiology, Oncology, Hematology, GI, Rare Diseases and CNS for pharma and biotech companies. His consulting experience extends also to the molecules and digital health solutions.

Giovanni holds a MS degree in Engineering from the University of Genoa and an MBA from SDA Bocconi and University of Michigan – Stephen Ross Business School.
Monica Mangone

Monica Mangone

Global Market Access Senior Consultant, Alira Health Experienced Market Access professional with 15+ years of experience in Healthcare and Pharmaceutical Industries, Monica worked at Novartis, Amgen and AstraZeneca prior to joining Alira Health.

Monica also managed several Dossier of P&R negotiations with AIFA, executed robust cross-functional National International and regional market access plan to support launches of new products (oncology and rare disease included).

Monica holds a BSc in Science and MSc in Health Economics from University of Milan, is currently a member of the HBA Healthcare Businesswomen's Association, and has been an ICF certified coach since 2000.
Our Delegates:
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access and Pricing, Alira Health
Veronica Ottobrino

Veronica Ottobrino

Analyst, Global Market Access, Alira Health

Would you like to meet Alira Health at XV Congresso Nazionale Sihta? Contact us to set up a meeting.

Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Events June 13, 2023
DSVR 2023
We are excited to share that we will be attending the DSVR 2023 - 15° Colloque Données de Santé en Vie Réelle.
France Real-World Evidence (RWE)
Blog May 4, 2023
How to Leverage Real-World Evidence to Achieve Orphan Drug Designation
Obtaining an orphan drug designation (ODD) is challenging and may require sponsors to leverage real-world evidence (RWE). Read the article to learn what ODD is, why it matters, and how RWE can help.
Orphan Drug Rare Disease Real-World Evidence (RWE)
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.